Nanoparticulation of Prodrug into Medicines for Cancer Therapy

Yuezhou Zhang; Huaguang Cui; Ruiqi Zhang; Hongbo Zhang; Wei Huang

doi:10.1002/advs.202101454

journal article Open Access Jul 29, 2021

Nanoparticulation of Prodrug into Medicines for Cancer Therapy

Yuezhou Zhang

Huaguang Cui Ruiqi Zhang

Hongbo Zhang

Wei Huang

Advanced Science Vol. 8 No. 18 · Wiley

View at Publisher Save 10.1002/advs.202101454

Abstract

AbstractThis article provides a broad spectrum about the nanoprodrug fabrication advances co‐driven by prodrug and nanotechnology development to potentiate cancer treatment. The nanoprodrug inherits the features of both prodrug concept and nanomedicine know‐how, attempts to solve underexploited challenge in cancer treatment cooperatively. Prodrugs can release bioactive drugs on‐demand at specific sites to reduce systemic toxicity, this is done by using the special properties of the tumor microenvironment, such as pH value, glutathione concentration, and specific overexpressed enzymes; or by using exogenous stimulation, such as light, heat, and ultrasound. The nanotechnology, manipulating the matter within nanoscale, has high relevance to certain biological conditions, and has been widely utilized in cancer therapy. Together, the marriage of prodrug strategy which shield the side effects of parent drug and nanotechnology with pinpoint delivery capability has conceived highly camouflaged Trojan horse to maneuver cancerous threats.

Topics

No keywords indexed for this article. Browse by subject →

References

263

[1]

10.1038/nrd.2018.46

[2]

10.1038/sj.bjc.6690646

[3]

10.1021/mp400272m

[4]

10.1002/anie.201604207

[5]

10.1177/0960327115603588

[6]

10.1016/j.nhtm.2014.12.002

[7]

10.1038/sj.clpt.6100400

[8]

10.1073/pnas.1515202112

[9]

10.1021/jacs.6b08313

[10]

10.1021/nn100869j

[11]

10.1021/acs.chemrev.8b00195

[12]

10.1016/j.jconrel.2019.03.015

[13]

10.1039/c7cs00521k

[14]

10.1021/mp300009u

[15]

10.1016/j.jconrel.2017.04.003

[16]

10.1016/j.actbio.2020.05.026

[17]

10.1016/j.ijpharm.2018.05.032

[18]

10.1016/j.jconrel.2017.08.034

[19]

10.1016/j.bmcl.2014.10.088

[20]

10.1021/acsnano.7b01522

[21]

10.1021/acsnano.8b03476

[22]

10.1016/j.jconrel.2016.03.037

[23]

10.1016/j.ejmech.2020.112365

[24]

10.1021/nl502044x

[25]

10.1021/bc400326y

[26]

10.1021/nn5065452

[27]

10.1016/j.jconrel.2018.11.032

[28]

10.1002/anie.201703492

[29]

10.1039/c6tb00612d

[30]

10.1021/acs.bioconjchem.7b00155

[31]

10.1002/asia.201601704

[32]

10.1093/annonc/mdq438

[33]

10.1016/j.biomaterials.2010.03.079

[34]

10.3109/1354750x.2012.715672

[35]

10.1002/smll.201601597

[36]

10.1016/j.ijpharm.2018.08.010

[37]

10.2217/nnm-2019-0261

[38]

10.1016/j.colsurfb.2018.02.046

[39]

10.1016/j.bmc.2017.04.025

[40]

10.1016/j.coph.2010.05.003

[41]

10.1002/adma.201300929

[42]

10.1039/c4py01156b

[43]

10.1021/acs.nanolett.6b01632

[44]

10.1016/j.jconrel.2018.07.010

[45]

10.1021/acs.jmedchem.8b00293

[46]

10.1021/acs.nanolett.8b00737

[47]

10.1016/j.msec.2018.04.048

[48]

10.1038/s41467-019-11193-x

[49]

10.3389/fphar.2020.552088

[50]

10.1021/nn1034197

Showing 50 of 263 references

Cited By

118

Stimuli-responsive polymer-dasatinib prodrug to reprogram cancer-associated fibroblasts for boosted immunotherapy

Yuxin Zhang, Yiyan Wang · 2025

Journal of Controlled Release

Metrics

118

Citations

263

References

Details

Published: Jul 29, 2021
Vol/Issue: 8(18)
License: View

Authors

Y

Yuezhou Zhang

Frontiers Science Center for Flexible Electronics (FSCFE) Xi'an Institute of Flexible Electronics (IFE) and Xi'an Institute of Biomedical Materials & Engineering (IBME) Northwestern Polytechnical University 127 West Youyi Road Xi'an 710072 China; Ningbo Institute of Northwestern Polytechnical University 218 Qingyi Road Ningbo 315103 China

H

Huaguang Cui

Frontiers Science Center for Flexible Electronics (FSCFE) Xi'an Institute of Flexible Electronics (IFE) and Xi'an Institute of Biomedical Materials & Engineering (IBME) Northwestern Polytechnical University 127 West Youyi Road Xi'an 710072 China; Ningbo Institute of Northwestern Polytechnical University 218 Qingyi Road Ningbo 315103 China

R

Ruiqi Zhang

Frontiers Science Center for Flexible Electronics (FSCFE) Xi'an Institute of Flexible Electronics (IFE) and Xi'an Institute of Biomedical Materials & Engineering (IBME) Northwestern Polytechnical University 127 West Youyi Road Xi'an 710072 China; Ningbo Institute of Northwestern Polytechnical University 218 Qingyi Road Ningbo 315103 China

H

Hongbo Zhang

Pharmaceutical Sciences Laboratory Åbo Akademi University Turku FI‐00520 Finland; Turku Bioscience Centre University of Turku and Åbo Akademi University Turku FI‐00520 Finland

W

Wei Huang

Frontiers Science Center for Flexible Electronics (FSCFE) Xi'an Institute of Flexible Electronics (IFE) and Xi'an Institute of Biomedical Materials & Engineering (IBME) Northwestern Polytechnical University 127 West Youyi Road Xi'an 710072 China; Ningbo Institute of Northwestern Polytechnical University 218 Qingyi Road Ningbo 315103 China

Funding

National Natural Science Foundation of China Award: 61935017

Fundamental Research Funds for the Central Universities

Sigrid Juséliuksen Säätiö

Northwestern Polytechnical University Award: 2020GXLH‐Z‐017

Academy of Finland Award: 328933

Cite This Article

Yuezhou Zhang, Huaguang Cui, Ruiqi Zhang, et al. (2021). Nanoparticulation of Prodrug into Medicines for Cancer Therapy. Advanced Science, 8(18). https://doi.org/10.1002/advs.202101454

Nanoparticulation of Prodrug into Medicines for Cancer Therapy

You May Also Like